Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

Empty drug store shelves in Phoenix, Arizona shortly after quarantine measures were announced. (Photo: Shutterstock)

Empty drug store shelves in Phoenix, Arizona shortly after quarantine measures were announced. (Photo: Shutterstock)

I Take Hydroxychloroquine. Please Don't Hoard It.

To prevent hoarding and protect public health, we need to move towards universal care and lower-cost drugs.

Olivia Alperstein

 by OtherWords

The best birthday present I got this year was a refill of my medication. Ordinarily, that wouldn’t be much to celebrate, but the coronavirus has upended the ordinary.

I’ve been taking hydroxychloroquine, an anti-malarial drug, since I was diagnosed with rheumatoid arthritis at 22. Thankfully, it’s kept my disease from progressing. It’s not an exaggeration to say it’s the only reason I don’t need a cane right now.

When I saw that chloroquine was being touted by President Trump and others as a potential treatment for the coronavirus, my heart sank. I counted the pills I had left and called my doctor.

Thankfully, I’m still getting my medication — for now.

It isn’t clear yet whether chloroquine is an effective treatment for COVID-19. There aren’t any definitive studies to prove it — in fact, a study in Brazil had to be halted over concerns about potentially fatal heart complications.

But that hasn’t stopped some doctors from using it to treat their COVID-19 patients. Some hospitals are stockpiling the drug in advance, while some people who haven’t tested positive — and who don’t need the drug for other medical reasons — are trying to get their hands on a supply.

As a result, I’m not the only person worrying about getting access to this life-saving medication.

Thousands upon thousands of people around the world rely on it, both to treat rheumatoid arthritis and to control malaria outbreaks. Imagine what it’s like for them watching otherwise healthy people try to stock up on this drug like they’re rushing to scoop up toilet paper.

Due to high costs, people already ration much-needed medications even in the best of times. And now, in a crisis, drug companies are angling to capitalize on this pandemic.

Drug maker Gilead, for example, sought — and received — a monopoly from the FDA to produce a promising coronavirus treatment, which would have surely put it out of reach for millions. The company only backed down after intense public pressure.

Before the outbreak, drug manufacturer Rising Pharmaceuticals had decided to double the price of Plaquenil, the brand-name version of hydroxychloroquine, but the company temporarily suspended the price hike. How nice of them.

Still, with banks reportedly encouraging drug companies to price gouge at will — and some U.S. senators more concerned with selling stock than protecting the public — it feels very vulnerable to rely on a life-saving medication at a time like this.

Anyone needing treatment for this virus should get it. But that also means we need to protect others who rely on drugs like chloroquine from the hoarding and price gouging that could put our medications out of reach, too.

No one — from coronavirus patients to people with conditions like mine — should feel like they need to hoard drugs to feel safe, or be deprived of access to drugs they need to survive.

If you are generally healthy, there’s something you can do to give people like me a fighting chance: Demand that Congress put people’s health first in the next coronavirus stimulus package. Call on them to require insurers to eliminate patient costs associated with treating the disease.

And call on them to move toward universal health care and lower-cost prescription drugs for all ailments.

I am incredibly lucky. Many people with rheumatoid arthritis have far worse symptoms than I and were first diagnosed later in life, when they may have developed other complications. These are people who are particularly vulnerable to COVID-19.

We have already lost too many people to this pandemic, and we will lose more. It’s more urgent than ever that we act to protect public health.

This work is licensed under a Creative Commons Attribution-Share Alike 3.0 License.
Olivia Alperstein

Olivia Alperstein

Olivia Alperstein is the Media Manager at the Institute for Policy Studies.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

Sanders, Top Dems Optimistic Party Will 'Come Together' for Reconciliation Package

However, House leaders warn they may miss a September 27 deadline to consider Senate-approved infrastructure legislation that progressives will only support alongside a $3.5 trillion bill.

Jessica Corbett ·

Report on Revolving Door and Tax Policy Sparks Calls for Federal Probe and Reforms

"This is an example of terrible management in the Treasury Department across multiple administrations."

Jessica Corbett ·

Nabisco Strike Ends After Union Members Approve New Contract

"Congratulations to these brave workers on their wins," said one labor writer. "May their determination and grit be an inspiration for workers everywhere."

Jessica Corbett ·

'I Had a Duty of Care': Doctor Praised for Violating Texas' New Abortion Ban

"I hope the law gets overturned," Dr. Alan Braid said, "and if this is what does it, that would be great."

Jessica Corbett ·

'Infuriating Disappointment': Biden DHS Ramping Up Deportations to Haiti

"It is unconscionable for the Biden administration to resume deportation flights to Haiti, despite the country's ongoing political, economic, and environmental disasters."

Jessica Corbett ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.

Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo